Patent · US Active

Anti-fibroblast activation protein antibodies and methods and uses thereof

US8999342B2 · kind B2 · utility

4Cited by

1References

9Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Christoph Renner · Partenstein, DE
Eliane Fischer · Brugg, CH
Stefan Bauer · Alzey, DE
Thomas Wuest · Bellinzona, CH

Key dates

Filing date	Oct 1, 2010
Grant date	Apr 7, 2015
Priority date	—
Expiry date	Oct 1, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.